Catalog No.
DHE16609
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG
Clonality
Monoclonal
Target
FLK-1, Kinase insert domain receptor, VEGFR2, Fetal liver kinase 1, CD309, Vascular endothelial growth factor receptor 2, Protein-tyrosine kinase receptor flk-1, FLK1, VEGFR-2, KDR
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P35968
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
UB-925, UB 925, UB925
Clone ID
UB-925
Transient intracellular expression of PD-L1 and VEGFR2 bispecific nanobody in cancer cells inspires long-term T cell activation and infiltration to combat tumor and inhibit cancer metastasis., PMID:40253320
Stromal PDGFR-beta expression is a prognostic factor in high-grade serous ovarian cancer patients but is it also predictive for response to antiangiogenic treatment?, PMID:39849231
Perfluoroalkyl substances (PFAS) exposure and preeclampsia risk: Impaired angiogenesis through suppression of VEGF signaling., PMID:39732411
The correlation between the number of endothelial progenitor cells in the peripheral blood and abdominal aortic aneurysm., PMID:39612386
Phase I study of BC001, a novel fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2, in advanced solid tumors., PMID:39562838
A critical analysis of design, binding pattern and SAR of benzo-fused heteronuclear compounds as VEGFR-2 inhibitors., PMID:39488171
Screening and anti-angiogenesis activity of Chiloscyllium plagiosum anti-human VEGFR2 single-domain antibody., PMID:39028612
Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma., PMID:39013886
Lack of VEGFA/KDR Signaling in Conventional Renal Cell Carcinoma Explains the Low Efficacy of Target Therapy and Frequent Adverse Events., PMID:39000466
Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II-III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study., PMID:38871690
Ramucirumab in combination with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma: a single-centre, phase 1/2 trial., PMID:38851207
Phase I/II Study of a Vascular Endothelial Growth Factor Receptor Vaccine in Patients With NF2-Related Schwannomatosis., PMID:38776485
Polyphyllin I ameliorates gefitinib resistance and inhibits the VEGF/VEGFR2/p38 pathway by targeting HIF-1a in lung adenocarcinoma., PMID:38761523
Apatinib potentiates the therapeutic effect of anti-PD-1 in locally advanced head and neck cancers., PMID:37846172
Circulating Endothelial Progenitor Cells and Their Relation to Thrombosis in Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia., PMID:35496969
Production and Conjugation of Truncated Recombinant Diphtheria Toxin to VEGFR-2 Specific Nanobody and Evaluation of its Cytotoxic Effect on PC-3 Cell Line., PMID:35478310
Docetaxel and 5-FU enhanced the inhibitory effects of apatinib and ramucirumab on growth and migration of gastric cancer., PMID:35235851
A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities., PMID:34925354
Gold nanoparticles enhance antibody effect through direct cancer cell cytotoxicity by differential regulation of phagocytosis., PMID:34737259
Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein., PMID:34668832
VEGF-VEGFR2 inhibitor-associated hyaline occlusive glomerular microangiopathy: a Japanese single-center experience., PMID:34115234
The Influence of KDR Genetic Variation on the Efficacy and Safety of Patients With Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen., PMID:34060368
An updated patent review of VEGFR-2 inhibitors (2017-present)., PMID:34043477
Heparin-binding VEGFR1 variants as long-acting VEGF inhibitors for treatment of intraocular neovascular disorders., PMID:34006633
Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma., PMID:33811482
The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab., PMID:33727583
Mutational and biophysical robustness in a prestabilized monobody., PMID:33617878
VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers., PMID:33410241
Pre-therapeutic Biomarkers for Ranibizumab Therapy among Type 2 Diabetic Patients with Diabetic Macular Edema., PMID:33394935
Pretreatment to Posttreatment Hypoxia Inducible Factor-1α Ratios as a Potentially Predictive Marker for First-Line Treatment in Nonsmall Cell Lung Cancer Patients without Known Driver Mutations., PMID:33347392
Hypoxia and proangiogenic proteins in human ameloblastoma., PMID:33067558
Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non-small Cell Lung Cancer., PMID:33046516
Is ramucirumab still the only second-line treatment in metastatic gastric cancer?, PMID:33030093
Surface grafting of Fc-binding peptides as a simple platform to immobilize and identify antibodies that selectively capture circulating endothelial progenitor cells., PMID:32902522
Glycation of fibronectin inhibits VEGF-induced angiogenesis by uncoupling VEGF receptor-2-c-Src crosstalk., PMID:32613750
NMR mapping of the highly flexible regions of 13C/15N-labeled antibody TTAC-0001-Fab., PMID:32415582
Zoledronate Inhibits Osteoclast Differentiation via Suppressing Vascular Endothelial Growth Factor Receptor 2 Expression., PMID:32274606
Thyroid Dysfunction Related to the Antiangiogenic VEGFR2-Binding Monoclonal Antibody Ramucirumab: A Series of 14 Cases and a Descriptive Study., PMID:32238718
Quantitative assessment and clinical relevance of VEGFRs-positive tumor cells in refractory brain tumors., PMID:32088190
Gene polymorphisms of VEGF and VEGFR2 are associated with the severity of Hashimoto's disease and the intractability of Graves' disease, respectively., PMID:32074519
The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research., PMID:32042194
Influencing factors of vascular endothelial function in patients with non-obstructive coronary atherosclerosis: a 1-year observational study., PMID:32000667
Endothelium capture-based liver segment imaging using vascular endothelial growth factor receptor 2 in preclinical ex vivo models., PMID:31965760
Association between vascular endothelial growth factor receptor 2 rs11941492 C/T polymorphism and Chinese Han patients in rheumatoid arthritis., PMID:31876763
A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2., PMID:31848332
Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab., PMID:31676953
Novel human Ab against vascular endothelial growth factor receptor 2 shows therapeutic potential for leukemia and prostate cancer., PMID:31578782
Regulation of VEGFR2 trafficking and signaling by Rab GTPase-activating proteins., PMID:31527750
Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma., PMID:31444999
A VEGFR2-MICA bispecific antibody activates tumor-infiltrating lymphocytes and exhibits potent anti-tumor efficacy in mice., PMID:31428800
For research use only. Not for human or drug use.
